Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006
Open Access
- 1 January 2013
- journal article
- research article
- Published by Medknow in Lung India
- Vol. 30 (1) , 20-6
Abstract
Background: To quantify the impact of bone metastasis and skeletal-related events (SREs) on mortality among older patients with lung cancer. Materials and Methods: Using the linked Surveillance, Epidemiology and End Results-Medicare database, we identified patients aged 65 years or older diagnosed with lung cancer between July 1, 1999 and December 31, 2005 and followed them to determine deaths through December 31, 2006. We classified patients as having possible bone metastasis and SREs using discharge diagnoses from inpatient claims and diagnoses paired with procedure codes from outpatient claims. We used Cox regression to estimate mortality hazards ratios (HR) among patients with bone metastasis with or without SRE, compared to patients without bone metastasis. Results: Among 126,123 patients with lung cancer having a median follow-up of 0.6 years, 24,820 (19.8%) had bone metastasis either at lung cancer diagnosis (9,523, 7.6%) or during follow-up (15,297, 12.1%). SREs occurred in 12,665 (51%) patients with bone metastasis. The HR for death was 2.4 (95% CI = 2.4-2.5) both for patients with bone metastasis but no SRE and for patients with bone metastasis plus SRE, compared to patients without bone metastasis. Conclusions: Having a bone metastasis, as indicated by Medicare claims, was associated with mortality among patients with lung cancer. We found no difference in mortality between patients with bone metastasis complicated by SRE and patients with bone metastasis but without SRE.Keywords
This publication has 32 references indexed in Scilit:
- Skeletal Disease Contributes Substantially to Morbidity and Mortality in Patients with Lung CancerClinical Lung Cancer, 2009
- Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumorsCancer, 2004
- The Cost of Treatment of Skeletal-Related Events in Patients with Bone Metastases from Lung CancerOncology, 2004
- Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.2002
- Biology of Osteoclast Activation in CancerJournal of Clinical Oncology, 2001
- Estimation of failure probabilities in the presence of competing risks: new representations of old estimatorsStatistics in Medicine, 1999
- Potential for Cancer Related Health Services Research Using a Linked Medicare-Tumor Registry DatabaseMedical Care, 1993
- Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning.Thorax, 1991
- Extrathoracic Staging of Bronchogenic CarcinomaChest, 1990
- RADIOISOTOPE SCANNING IN INITIAL STAGING OF BRONCHOGENIC CARCINOMA1978